A wonderful look at the future and the power of believing there is a new way of #CVPrev! Thank you Verve Therapeutics Sek Kathiresan MD et al for sharing the excitement with us today ASPC Dr. Payal Kohli, MD

Tomorrow is the last day to submit nominations for the Douglas P. Zipes Distinguished Young Scientist Award! This award recognizes young physician scientists who have made contributions to the field of CVD & have an impressive body of scientific research. bit.ly/3wp12d7

2Q Earnings Verve Therapeutics Continued progress: 1. Heart-2 trial testing VERVE-102 is enrolling 2. Heart-2 and PCSK9 program data update planned for first half of 2025 3. $576M in cash, runway into late 2026 4. Rest of cholesterol-lowering pipeline (VERVE-201 targeting ANGPTL3

#CVCT2024 : Join the discussion on GENE THERAPY FOR GENETIC AND FOR COMMON HEART DISEASES. PROGRESSING INTO CLINICAL STAGE, December 9-11, 2024, Washington DC ! Browse the program and register to attend : globalcvctforum.com/scientific-pro… #CVCT #clinicaltrials #genetherapy

Congratulations to our lab's newest NIH K-awardees Sumeet Khetarpal and Mu A! 🥳

On #GivingTuesday2024, consider supporting our efforts to discover and understand reasons why heart disease and diabetes are common among South Asian individuals 💜 ourhealthstudy.org 🙏 because.massgeneral.org/campaign/our-h…

Two-year advanced training award & mentorship program for senior fellows & junior faculty in c/t research.⁠ This award provides two years of salary support at 75% of the awardee’s institutional salary base within NIH guidelines. ⁠Apply by March 21: hvrdct.me/4z9

🎉Exciting news! 🎉 The OurHealth team is proud to share that we’ve collected *1,000 samples* & have registered over *2,500 participants* since the study’s launch in October 2023. 💜 ourhealthstudy.org [1/x]

☝️A must read article “Gene therapy and genome editing for lipoprotein disorders” provides a comprehensive and timely overview of how advances in genetic medicine—including AAV gene addition, CRISPR editing, and RNA-based strategies—are reshaping the prevention and management

The CVRC welcomes new resident member Sumeet Khetarpal, MD, PhD. Dr. Khetarpal joins us from MGH, recently received the Burroughs Wellcome Fund Career Award, and just published his first UVA School of Medicine-affiliated paper in Nature Cardiovascular Research! Read more: cvrc.virginia.edu/skhetarpal-joi…

We are hiring! Delighted to share an opportunity to join the clinical development team at Verve Therapeutics Eli Lilly and Company , where we are on a mission to transform the care of ASCVD through single-course gene editing medicines! Apply here: lnkd.in/eVDDP85i

Exciting job posting for Human Genomics and Translational Data Sciences Lead Eli Lilly and Company! High impact role working alongside the leaders in cardiometabolic drug dev. Access to large biobanks + world-unique internal deep phenotyping data. Apply @ careers.lilly.com/us/en/job/R-93…